Analyst consensus rating
BioLineRx Analyst Rating: none
Direct answer
BioLineRx's consensus rating is none.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $22.00.
Forecast evidence checked September 30, 2026.
Get free BioLineRx email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.36
- Average price target
- $22.00
- High price target
- $26.00
- Low price target
- $18.00
- Low target gap
- +662.7%
- Target upside
- +832.2%
- High target gap
- +1,001.7%
- Target range width
- 339%
- Consensus rating
- none
- Analysts
- 2
- Evidence date
- September 30, 2026
- Valid through
- October 7, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for BioLineRx?
BioLineRx has a verified none consensus. The same dataset has an average price target of $22.00.
How far are BioLineRx's low and high targets from the recorded price?
The low target implies +662.7%, while the high target implies +1,001.7%.
How many analysts are included in BioLineRx's consensus?
The verified consensus includes 2 analysts.
How is BioLineRx's target upside or downside calculated?
The average target of $22.00 is divided by the recorded price of $2.36, then one is subtracted to produce +832.2%. This does not guarantee a future return.
When was BioLineRx's analyst forecast verified?
The data was verified on 2026-09-30. The dataset is valid through 2026-10-07.